Objective To study the effect of daggligin on glucose metabolism and cardiac function in patients with acute myocardial infarction (AMI) and type 2 diabetes after percutaneous coronary intervention (PCI). Methods All 114 patients with AMI with type 2 diabetes from August 2023 to June 2024, who received PCI in the catheterization room of our hospital, the control group was treated with insulin and original oral hypoglycemic drugs, and the observation group was administered dagliflozin on the basis of the control group. Results The fasting blood glucose and hemoglobin levels of patients in the observation group were lower than those in the control group (P<0.05). In terms of comparison of cardiac function indicators, the LVEDD and ESVI of the observation group were lower than those of the control group, and LVEF and LVMI were both higher than those of the control group (P<0.05). Comparison of myocardial TIMI flow frames (CTFC) and myocardial perfusion grade (TMPG) after 6 months of treatment, The observation group was lower than that of the control group (P<0.05). Follow-up visits ranged from 6 to 12 months, the incidence of MACE and heart failure in the observation group were lower than that in the control group (P<0.05). The difference in the incidence of adverse drug reactions was not significant (P> 0.05). Conclusions The application of daggligin in the hypoglycemic program after PCI intervention in patients with AMI and diabetes has a positive effect, can promote blood sugar control, improve patients' cardiac function, reduce cardiovascular adverse events, and has high safety.